# A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

> **NCT01346540** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 16 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BIBF 1120
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01346540
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-14
- **Primary completion:** 2013-04-25
- **Final completion:** 2017-01-17
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01346540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01346540, "A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01346540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*